Novo Nordisk Shares Face Mounting Challenges Amid Supply and Competitive Pressures

Novo Nordisk finds itself navigating one of its most challenging periods in the stock market for years. The pharmaceutical company, once a dominant star in the obesity treatment sector, has seen its valuation erode significantly as competitor Eli Lilly captures market attention. A confluence of regulatory risks, supply chain concerns, and pipeline developments is now creating a complex pressure point for the firm.

Regulatory and Supply Chain Headwinds Intensify

A recent warning letter from the U.S. Food and Drug Administration (FDA) has applied the most immediate downward pressure on the share price. The regulatory action targets a production facility in Indiana operated by contract manufacturer Catalent, a critical link in Novo Nordisk’s supply chain for the crucial U.S. market.

This FDA intervention has raised serious doubts about supply reliability stateside. Following the news, the stock closed down approximately 3% late last week and has continued to trade at markedly lower levels. Investors are concerned that potential production bottlenecks could further weaken Novo Nordisk’s competitive stance against Eli Lilly, whose supply chain has recently appeared more stable.

This decline compounds an already difficult year for the equity. Since the start of the year, the share price has lost roughly half its value in euro terms, trading approximately 50% below its 52-week high. From a technical perspective, the price is now firmly below its 200-day moving average, confirming a broader downward trend.

Pipeline Progress Contrasts with Competitive Realities

Management is attempting to counter these operational issues with advancements in its drug pipeline. The current market sentiment is being shaped by two opposing forces.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

• CagriSema Submission: On December 18, 2025, Novo Nordisk formally submitted CagriSema for FDA approval. This once-weekly treatment combines a GLP-1 agent with an amylin analogue and is viewed as a potential “next-generation” therapy for weight management, promising higher efficacy than the company’s own Wegovy. Many market observers see CagriSema as a pivotal component for reclaiming lost ground in the obesity market.
• Eli Lilly’s Growth Leadership: While Novo Nordisk contends with challenges, its U.S. rival is demonstrating formidable momentum. Eli Lilly reported that third-quarter revenue for its drug Zepbound surged 185% year-over-year. In contrast, growth in Novo Nordisk’s obesity care segment appeared more modest at 12%. This dynamic has shifted market perception decisively in favor of Eli Lilly.
• Analyst Sentiment Shifts: This trend is reflected in analysis from major financial institutions. Firms including BMO Capital and Bernstein have recently reaffirmed their “outperform” ratings for Eli Lilly, indirectly highlighting institutional investor preference. This reinforces the perception that capital flows are increasingly directed toward the U.S. competitor.

Adding another layer, the European Medicines Agency (EMA) recommended a new, higher dose of Wegovy on December 12, citing weight reduction data of 20.7%. While these fundamental efficacy results are positive, they are currently being overshadowed in the market by noise surrounding supply chains and competitive pressures.

Technical Picture Remains Bearish Despite Potential Catalysts

The chart analysis presents a clearly negative outlook. Recent data shows the stock is down nearly 60% year-over-year, having lost over two-thirds of its value since its mid-2024 peaks. This steep decline results from a significant market re-rating and a “reality check” within the GLP-1 boom, where expectations are being realigned with actual market share dynamics.

Currently, the shares are attempting to establish a base just above recent annual lows. A 30-day volatility reading above 35% underscores the nervous trading behavior, particularly among professional investors. The Relative Strength Index (RSI) sits around 35, indicating a weakened but not extremely oversold condition.

Whether the combination of the CagriSema application and Wegovy’s improved efficacy data can restore investor confidence in 2026 depends heavily on Novo Nordisk’s ability to swiftly resolve the production and supply chain issues highlighted by the FDA. If supply stabilizes, pipeline progress may regain prominence. However, if operational hurdles persist, Eli Lilly’s dominant growth advantage is likely to maintain intense pressure on the stock.